|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005558,
umls-concept:C0030705,
umls-concept:C0033522,
umls-concept:C0033572,
umls-concept:C0138741,
umls-concept:C0205210,
umls-concept:C0205265,
umls-concept:C0231449,
umls-concept:C0332161,
umls-concept:C0376358,
umls-concept:C0439275,
umls-concept:C0439810,
umls-concept:C0542559,
umls-concept:C0597298,
umls-concept:C0681842,
umls-concept:C1274040,
umls-concept:C1555582
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-6-27
|
|
pubmed:abstractText |
Total prostate-specific antigen (tPSA), ratio of free PSA (fPSA) to tPSA (%fPSA), and PSA density (PSAD) testing have a very low accuracy in the detection of prostate cancer (PCa). There is an urgent need for more accurate biomarkers.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1873-7560
|
|
pubmed:author |
pubmed-author:BiniVittorioV,
pubmed-author:CeriottiFerruccioF,
pubmed-author:DorigattiFernandaF,
pubmed-author:FreschiMassimoM,
pubmed-author:GuazzoniGiorgioG,
pubmed-author:LazzeriMassimoM,
pubmed-author:LughezzaniGiovanniG,
pubmed-author:MaccagnanoCarmenC,
pubmed-author:MontorsiFrancescoF,
pubmed-author:NavaLucianoL,
pubmed-author:PontilloMarinaM,
pubmed-author:RigattiPatrizioP,
pubmed-author:ScattoniVincenzoV
|
|
pubmed:copyrightInfo |
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
214-22
|
|
pubmed:meshHeading |
pubmed-meshheading:21482022-Academic Medical Centers,
pubmed-meshheading:21482022-Aged,
pubmed-meshheading:21482022-Biopsy,
pubmed-meshheading:21482022-Health Status Indicators,
pubmed-meshheading:21482022-Humans,
pubmed-meshheading:21482022-Italy,
pubmed-meshheading:21482022-Logistic Models,
pubmed-meshheading:21482022-Male,
pubmed-meshheading:21482022-Middle Aged,
pubmed-meshheading:21482022-Neoplasm Staging,
pubmed-meshheading:21482022-Predictive Value of Tests,
pubmed-meshheading:21482022-Prognosis,
pubmed-meshheading:21482022-Prostate-Specific Antigen,
pubmed-meshheading:21482022-Prostatic Neoplasms,
pubmed-meshheading:21482022-ROC Curve,
pubmed-meshheading:21482022-Risk Assessment,
pubmed-meshheading:21482022-Risk Factors,
pubmed-meshheading:21482022-Ultrasonography, Interventional
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
|
|
pubmed:affiliation |
Department of Urology, San Raffaele Turro, Vita-Salute San Raffaele University, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
